Novavax Inc (NVAX) support and resistance · P/E 2.5, rev $682.2M
Novavax Inc (NVAX) is a biotechnology company listed on US.
This page maps Novavax Inc (NVAX) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported NVAX revenue for 2024-12-31 was $682.2M. Net income was -$187.5M. Revenue was down 30.7% from 2023-12-31 to 2024-12-31. NVAX currently screens at market cap $1.09B and trailing P/E 2.5.
NVAX currently screens at market cap $1.09B and trailing P/E 2.5. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new NVAX 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the NVAX quote page for the session range and the stock page for the full model.
Not investment advice.